{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:29:44Z","timestamp":1793158184613,"version":"4.5.0"},"reference-count":112,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1093\/jnci\/dju380","type":"journal-article","created":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T01:10:56Z","timestamp":1417396256000},"source":"Crossref","is-referenced-by-count":123,"title":["Cost-effectiveness of Population Screening for BRCA Mutations in Ashkenazi Jewish Women Compared With Family History\u2013Based Testing"],"prefix":"10.1093","volume":"107","author":[{"given":"Ranjit","family":"Manchanda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Legood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Burnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Raikou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Loggenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Wardle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Sanderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Gessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Side","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nyala","family":"Balogun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakshit","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajith","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huw","family":"Dorkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Wallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Tomlinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uziel","family":"Beller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usha","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,11,28]]},"reference":[{"key":"key\n\t\t\t\t20170520215915_CIT0001","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.1513","article-title":"Identification of BRCA1\/BRCA2 carriers by screening in the healthy population and its implications. In: American Society of Clinical Oncology, Annual meeting","volume":"29","author":"Levy-Lahad","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"key\n\t\t\t\t20170520215915_CIT0002","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1086\/302320","article-title":"The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews","volume":"64","author":"Hartge","year":"1999","journal-title":"Am J Hum Genet"},{"issue":"3","key":"key\n\t\t\t\t20170520215915_CIT0003","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1200\/JCO.2009.25.0712","article-title":"Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women","volume":"28","author":"Metcalfe","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5645","key":"key\n\t\t\t\t20170520215915_CIT0004","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","article-title":"Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2","volume":"302","author":"King","year":"2003","journal-title":"Science"},{"issue":"9","key":"key\n\t\t\t\t20170520215915_CIT0005","first-page":"741","article-title":"Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study","volume":"8","author":"Hopper","year":"1999","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"11","key":"key\n\t\t\t\t20170520215915_CIT0006","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/jnci\/91.11.943","article-title":"Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer","volume":"91","author":"Peto","year":"1999","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"key\n\t\t\t\t20170520215915_CIT0007","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S0090-8258(03)00152-5","article-title":"Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in israel","volume":"89","author":"Hirsh-Yechezkel","year":"2003","journal-title":"Gynecol Oncol"},{"issue":"11","key":"key\n\t\t\t\t20170520215915_CIT0008","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.ejca.2007.04.023","article-title":"Genetic epidemiology of BRCA mutations--family history detects less than 50% of the mutation carriers","volume":"43","author":"Moller","year":"2007","journal-title":"Eur J Cancer"},{"issue":"4","key":"key\n\t\t\t\t20170520215915_CIT0009","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ijc.11271","article-title":"Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: a population-based study","volume":"106","author":"de Sanjose","year":"2003","journal-title":"Int J Cancer"},{"issue":"10","key":"key\n\t\t\t\t20170520215915_CIT0010","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/nbt1486","article-title":"Next-generation DNA sequencing","volume":"26","author":"Shendure","year":"2008","journal-title":"Nat Biotechnol"},{"issue":"8","key":"key\n\t\t\t\t20170520215915_CIT0011","first-page":"E153","article-title":"Population-based testing for brca1\/2 mutations does not cause short term psychological harm: results from a randomized trial (GCaPPS)","volume":"22","author":"Manchanda","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"key\n\t\t\t\t20170520215915_CIT0012","doi-asserted-by":"crossref","first-page":"d1766","DOI":"10.1136\/bmj.d1766","article-title":"Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting","volume":"342","author":"Petrou","year":"2011","journal-title":"BMJ"},{"issue":"4","key":"key\n\t\t\t\t20170520215915_CIT0013","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/ijc.20458","article-title":"Genetic counseling program in familial breast cancer: analysis of its effectiveness, cost and cost-effectiveness ratio","volume":"112","author":"Balmana","year":"2004","journal-title":"Int J Cancer"},{"issue":"6","key":"key\n\t\t\t\t20170520215915_CIT0014","doi-asserted-by":"crossref","first-page":"397","DOI":"10.7326\/0003-4819-144-6-200603210-00006","article-title":"Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation","volume":"144","author":"Anderson","year":"2006","journal-title":"Ann Intern Med"},{"issue":"3","key":"key\n\t\t\t\t20170520215915_CIT0015","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s10689-011-9444-z","article-title":"A cost-effectiveness analysis of prophylactic surgery versus gynecologic surveillance for women from hereditary non-polyposis colorectal cancer (HNPCC) Families","volume":"10","author":"Yang","year":"2011","journal-title":"Familial Cancer"},{"issue":"2","key":"key\n\t\t\t\t20170520215915_CIT0016","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/cncr.23554","article-title":"Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch syndrome","volume":"113","author":"Kwon","year":"2008","journal-title":"Cancer"},{"issue":"9","key":"key\n\t\t\t\t20170520215915_CIT0017","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/GIM.0b013e3181afd322","article-title":"Cost-effectiveness of population-based BRCA1\/2 testing and ovarian cancer prevention for Ashkenazi Jews: a call for dialogue","volume":"11","author":"Rubinstein","year":"2009","journal-title":"Genet Med"},{"key":"key\n\t\t\t\t20170520215915_CIT0018","volume-title":"Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation","author":"Nelson","year":"2013"},{"key":"key\n\t\t\t\t20170520215915_CIT0019","article-title":"Familial breast cancer: Classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer","volume-title":"NICE clinical guideline CG164 ed","author":"NICE","year":"2013"},{"issue":"2","key":"key\n\t\t\t\t20170520215915_CIT0020","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/jama.296.2.185","article-title":"Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation","volume":"296","author":"Finch","year":"2006","journal-title":"JAMA"},{"issue":"2","key":"key\n\t\t\t\t20170520215915_CIT0021","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djn442","article-title":"Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers","volume":"101","author":"Rebbeck","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"key\n\t\t\t\t20170520215915_CIT0022","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1200\/JCO.2004.04.188","article-title":"Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group","volume":"22","author":"Rebbeck","year":"2004","journal-title":"J Clin Oncol"},{"issue":"9880","key":"key\n\t\t\t\t20170520215915_CIT0023","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/S0140-6736(13)60140-3","article-title":"Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data","volume":"381","author":"Cuzick","year":"2013","journal-title":"Lancet"},{"issue":"24","key":"key\n\t\t\t\t20170520215915_CIT0024","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.1200\/JCO.2005.03.909","article-title":"Screening for familial ovarian cancer: the need for well-designed prospective studies","volume":"23","author":"Jacobs","year":"2005","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20170520215915_CIT0025","article-title":"Guide to the methods of technology appraisal","volume-title":"N1618 ed","author":"NICE","year":"2008"},{"key":"key\n\t\t\t\t20170520215915_CIT0026","article-title":"Jews in Britain: a snapshot from the 2001 Census","author":"Graham","year":"2007"},{"key":"key\n\t\t\t\t20170520215915_CIT0027","first-page":"182","article-title":"Census 2001: National report for England and Wales, Part1, Section-2. Table S149: Sex and age by religion","author":"Office of National Statistics","year":"2003"},{"key":"key\n\t\t\t\t20170520215915_CIT0028","article-title":"Unit Costs of Health and Social Care 2011","author":"Curtis","year":"2011"},{"key":"key\n\t\t\t\t20170520215915_CIT0029","volume-title":"Lifetable for females in the UK","author":"Office of National Statistics"},{"issue":"7","key":"key\n\t\t\t\t20170520215915_CIT0030","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1136\/jmg.2006.048173","article-title":"Cancer risks in carriers of the BRCA1\/2 Ashkenazi founder mutations","volume":"44","author":"Kadouri","year":"2007","journal-title":"J Med Genet"},{"issue":"17","key":"key\n\t\t\t\t20170520215915_CIT0031","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1001\/jama.283.17.2260","article-title":"Clinicopathologic features of BRCA-linked and sporadic ovarian cancer","volume":"283","author":"Boyd","year":"2000","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170520215915_CIT0032","volume-title":"Surveillance Epidemiology and End Results. SEER Stat Fact Sheets: Ovary 2005\u20132009","author":"SEER"},{"key":"key\n\t\t\t\t20170520215915_CIT0033","article-title":"Cancer Registrations in England","author":"ONS","year":"2010"},{"key":"key\n\t\t\t\t20170520215915_CIT0034","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1038\/sj.bjc.6605401","article-title":"What if cancer survival in Britain were the same as in Europe: how many deaths are avoidable?","volume":"101","author":"Abdel-Rahman","year":"2009","journal-title":"Br J Cancer"},{"issue":"4","key":"key\n\t\t\t\t20170520215915_CIT0035","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jama.2012.20","article-title":"Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer","volume":"307","author":"Bolton","year":"2012","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170520215915_CIT0036","article-title":"Cancer survival in England: one-year and five-year survival for 21 common cancers, by sex and age","author":"Walters","year":"(2010)","journal-title":"Office for National Statistics, Statistical Bulletin"},{"issue":"1","key":"key\n\t\t\t\t20170520215915_CIT0037","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10549-009-0566-z","article-title":"Prognosis of BRCA-associated breast cancer: a summary of evidence","volume":"119","author":"Bordeleau","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"key\n\t\t\t\t20170520215915_CIT0038","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa070608","article-title":"Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations","volume":"357","author":"Rennert","year":"2007","journal-title":"N Engl J Med"},{"issue":"28","key":"key\n\t\t\t\t20170520215915_CIT0039","doi-asserted-by":"crossref","first-page":"6890","DOI":"10.1200\/JCO.2005.02.626","article-title":"Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer","volume":"23","author":"Madalinska","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"key\n\t\t\t\t20170520215915_CIT0040","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ygyno.2008.12.026","article-title":"Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment","volume":"113","author":"Havrilesky","year":"2009","journal-title":"Gynecol Oncol"},{"key":"key\n\t\t\t\t20170520215915_CIT0041","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198529446.001.0001","volume-title":"Methods for the economic evaluation of health care programs","author":"Drummond","year":"2005","edition":"Third"},{"key":"key\n\t\t\t\t20170520215915_CIT0042","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1634\/theoncologist.7-suppl_5-20","article-title":"Relapsed ovarian cancer: challenges and management strategies for a chronic disease","volume":"7","author":"Armstrong","year":"2002","journal-title":"Oncologist"},{"key":"key\n\t\t\t\t20170520215915_CIT0043","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/cncr.2820710205","article-title":"Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality","volume":"71","author":"Yancik","year":"1993","journal-title":"Cancer"},{"key":"key\n\t\t\t\t20170520215915_CIT0044","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2007.25.18_suppl.5509","article-title":"Long-term follow-up of women enrolled in a randomized trial of adjuvant chemotherapy for early stage ovarian cancer","volume-title":"ASCO Annual Meeting Proceedings (Part I). 2007","author":"Swart"},{"issue":"6","key":"key\n\t\t\t\t20170520215915_CIT0045","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/bjc.2012.30","article-title":"Variation in advanced stage at diagnosis of lung and female breast cancer in an English region 2006\u20132009","volume":"106","author":"Lyratzopoulos","year":"2012","journal-title":"Br J Cancer"},{"key":"key\n\t\t\t\t20170520215915_CIT0046","article-title":"Breast Cancer Incidence Statistics UK 2009\u20132011","volume-title":"Breast Cancer (C50), Average Number of New Cases per Year and Age-Specific Incidence Rates, Females, UK, 2009\u20132011","author":"CRUK","year":"(2012)"},{"key":"key\n\t\t\t\t20170520215915_CIT0047","article-title":"National costing report: Early and locally advanced breast cancer\/Advanced breast cancer","author":"NICE","year":"2009"},{"key":"key\n\t\t\t\t20170520215915_CIT0048","article-title":"Registrations of cancer diagnosed in 2006, England","author":"ONS","year":"(2008)","journal-title":"Cancer Statistics Registrations, The Office for National Statistics"},{"issue":"9","key":"key\n\t\t\t\t20170520215915_CIT0049","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1158\/1055-9965.EPI-11-1196","article-title":"Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combined","volume":"21","author":"Heijnsdijk","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"key\n\t\t\t\t20170520215915_CIT0050","article-title":"Advanced breast cancer: diagnosis and treatment","author":"NICE. Clinical Guideline (CG81)","year":"2009"},{"issue":"5","key":"key\n\t\t\t\t20170520215915_CIT0051","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1586\/erp.10.65","article-title":"Health-state utility values in breast cancer","volume":"10","author":"Peasgood","year":"2010","journal-title":"Expert review of pharmacoeconomics & outcomes research"},{"issue":"8","key":"key\n\t\t\t\t20170520215915_CIT0052","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1002\/cncr.21359","article-title":"Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies","volume":"104","author":"Gennari","year":"2005","journal-title":"Cancer"},{"key":"key\n\t\t\t\t20170520215915_CIT0053","article-title":"Social value judgements: principles for the development of NICE guidance","volume-title":"(NICE) NIfHaCE","author":"NICE","year":"2008","edition":"2nd"},{"issue":"29","key":"key\n\t\t\t\t20170520215915_CIT0054","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta13290","article-title":"Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making","volume":"13","author":"Andronis","year":"2009","journal-title":"Health technology assessment"},{"issue":"1","key":"key\n\t\t\t\t20170520215915_CIT0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1524-4733.2005.08101.x","article-title":"Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty","volume":"8","author":"Briggs","year":"2005","journal-title":"Value Health"},{"key":"key\n\t\t\t\t20170520215915_CIT0056","article-title":"Familial breast cancer: The classification and careof women at risk of familial breast cancer in primary, secondary and tertiary care","author":"NICE","year":"2006"},{"issue":"7","key":"key\n\t\t\t\t20170520215915_CIT0057","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/sj.bjc.6603356","article-title":"Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer","volume":"95","author":"Griebsch","year":"2006","journal-title":"Br J Cancer"},{"issue":"3","key":"key\n\t\t\t\t20170520215915_CIT0058","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1586\/14737167.5.3.235","article-title":"Paclitaxel: cost-effectiveness in ovarian cancer","volume":"5","author":"Dedes","year":"2005","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"key\n\t\t\t\t20170520215915_CIT0059","article-title":"Guidance on the use of paclitaxel in the treatment of ovarian cancer","author":"NICE","year":"(2003)"},{"issue":"2","key":"key\n\t\t\t\t20170520215915_CIT0060","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/ng1096-185","article-title":"Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2","volume":"14","author":"Roa","year":"1996","journal-title":"Nat Genet"},{"issue":"11","key":"key\n\t\t\t\t20170520215915_CIT0061","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","article-title":"Meta-analysis of BRCA1 and BRCA2 penetrance","volume":"25","author":"Chen","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"key\n\t\t\t\t20170520215915_CIT0062","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1471-0528.2011.03257.x","article-title":"Factors influencing uptake and timing of risk-reducing salpingo-oophorectomy in women at risk of familial ovarian cancer: a competing risk time to event analysis","volume":"119","author":"Manchanda","year":"2012","journal-title":"BJOG"},{"issue":"1","key":"key\n\t\t\t\t20170520215915_CIT0063","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ygyno.2010.12.326","article-title":"The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation","volume":"121","author":"Finch","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"2","key":"key\n\t\t\t\t20170520215915_CIT0064","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0090-8258(03)00072-6","article-title":"Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy","volume":"89","author":"Robson","year":"2003","journal-title":"Gynecol Oncol"},{"issue":"2","key":"key\n\t\t\t\t20170520215915_CIT0065","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.maturitas.2005.04.009","article-title":"The association between early menopause and risk of ischaemic heart disease: influence of Hormone Therapy","volume":"53","author":"Lokkegaard","year":"2006","journal-title":"Maturitas"},{"issue":"1","key":"key\n\t\t\t\t20170520215915_CIT0066","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ygyno.2008.12.024","article-title":"A controlled study of mental distress and somatic complaints after risk-reducing salpingo-oophorectomy in women at risk for hereditary breast ovarian cancer","volume":"113","author":"Michelsen","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"22","key":"key\n\t\t\t\t20170520215915_CIT0067","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.2005.05.1896","article-title":"The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy","volume":"24","author":"Madalinska","year":"2006","journal-title":"J Clin Oncol"},{"issue":"1","key":"key\n\t\t\t\t20170520215915_CIT0068","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ogrm.2008.11.003","article-title":"Hormone replacement therapy: a 2008 perspective","volume":"19","author":"MacLennan","year":"2008","journal-title":"Obstet Gynecol Reprod Med"},{"issue":"3","key":"key\n\t\t\t\t20170520215915_CIT0069","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3109\/13697137.2011.570590","article-title":"Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health","volume":"14","author":"Sturdee","year":"2011","journal-title":"Climacteric"},{"issue":"31","key":"key\n\t\t\t\t20170520215915_CIT0070","doi-asserted-by":"crossref","first-page":"7804","DOI":"10.1200\/JCO.2004.00.8151","article-title":"Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group","volume":"23","author":"Rebbeck","year":"2005","journal-title":"J Clin Oncol"},{"issue":"8","key":"key\n\t\t\t\t20170520215915_CIT0071","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1158\/1055-9965.EPI-09-0171","article-title":"Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent","volume":"18","author":"Evans","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"key\n\t\t\t\t20170520215915_CIT0072","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1399-0004.2009.01329.x","article-title":"Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing","volume":"77","author":"Skytte","year":"2010","journal-title":"Clin Genet"},{"issue":"11","key":"key\n\t\t\t\t20170520215915_CIT0073","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3816\/CBC.2007.n.053","article-title":"Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers","volume":"7","author":"Friebel","year":"2007","journal-title":"Clin Breast Cancer"},{"issue":"7","key":"key\n\t\t\t\t20170520215915_CIT0074","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1158\/1055-9965.EPI-12-0149","article-title":"A Simulation Model to Predict the Impact of Prophylactic Surgery and Screening on the Life Expectancy of BRCA1 and BRCA2 Mutation Carriers","volume":"21","author":"Sigal","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"24","key":"key\n\t\t\t\t20170520215915_CIT0075","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1200\/JCO.2007.13.9568","article-title":"Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: a prospective 1-year follow-up study","volume":"26","author":"Brandberg","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10","key":"key\n\t\t\t\t20170520215915_CIT0076","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.bjps.2007.08.006","article-title":"Aesthetic outcome, patient satisfaction, and health-related quality of life in women at high risk undergoing prophylactic mastectomy and immediate breast reconstruction","volume":"61","author":"Isern","year":"2008","journal-title":"J Plast Reconstr Aesthet Surg"},{"issue":"1","key":"key\n\t\t\t\t20170520215915_CIT0077","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejso.2011.10.010","article-title":"Less correspondence between expectations before and cosmetic results after risk-reducing mastectomy in women who are mutation carriers: a prospective study","volume":"38","author":"Brandberg","year":"2012","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"key\n\t\t\t\t20170520215915_CIT0078","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/pon.726","article-title":"Psychosocial functioning in women who have undergone bilateral prophylactic mastectomy","volume":"13","author":"Metcalfe","year":"2004","journal-title":"Psychooncology"},{"issue":"4","key":"key\n\t\t\t\t20170520215915_CIT0079","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1365-2354.2010.01204.x","article-title":"High satisfaction rate ten years after bilateral prophylactic mastectomy - a longitudinal study","volume":"20","author":"Wasteson","year":"2011","journal-title":"Eur J Cancer Care (Engl)"},{"key":"key\n\t\t\t\t20170520215915_CIT0080","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.2105\/AJPH.85.8_Pt_1.1133","article-title":"Women\u2019s receptivity to testing for a genetic susceptibility to breast cancer","volume":"85","author":"Chaliki","year":"1995","journal-title":"Am J Public Health"},{"issue":"1","key":"key\n\t\t\t\t20170520215915_CIT0081","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/(SICI)1096-8628(19970110)68:1<43::AID-AJMG8>3.0.CO;2-Z","article-title":"Genetic testing for breast cancer susceptibility: awareness and interest among women in the general population","volume":"68","author":"Tambor","year":"1997","journal-title":"Am J Med Genet"},{"issue":"2","key":"key\n\t\t\t\t20170520215915_CIT0082","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/1096-8628(2000)9999:999<00::AID-AJMG1142>3.0.CO;2-I","article-title":"Women\u2019s interest in genetic testing for breast cancer susceptibility may be based on unrealistic expectations","volume":"99","author":"Press","year":"2001","journal-title":"Am J Med Genet"},{"issue":"5","key":"key\n\t\t\t\t20170520215915_CIT0083","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1034\/j.1399-0004.2000.570508.x","article-title":"Perceptions of Ashkenazi Jewish breast cancer patients on genetic testing for mutations in BRCA1 and BRCA2","volume":"57","author":"Phillips","year":"2000","journal-title":"Clin Genet"},{"key":"key\n\t\t\t\t20170520215915_CIT0084","volume-title":"Ovarian Cancer - UK Incidence Statistics","author":"CRUK"},{"key":"key\n\t\t\t\t20170520215915_CIT0085","article-title":"Cancer Registration Statistics, England, 2011","author":"ONS","year":"(2013)","journal-title":"Office for National Statistics"},{"issue":"2","key":"key\n\t\t\t\t20170520215915_CIT0086","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/1097-0142(20010715)92:2<440::AID-CNCR1340>3.0.CO;2-O","article-title":"The frequency of founder mutations in the BRCA1, BRCA2, and APC genes in Australian Ashkenazi Jews: implications for the generality of U.S. population data","volume":"92","author":"Bahar","year":"2001","journal-title":"Cancer"},{"key":"key\n\t\t\t\t20170520215915_CIT0087","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/1471-2407-8-155","article-title":"Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast\/ovarian cancer quoted should reflect the cancer burden in the family","volume":"8","author":"Evans","year":"2008","journal-title":"BMC Cancer"},{"issue":"3","key":"key\n\t\t\t\t20170520215915_CIT0088","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/GIM.0b013e318163487d","article-title":"Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers","volume":"10","author":"Bradbury","year":"2008","journal-title":"Genet Med"},{"key":"key\n\t\t\t\t20170520215915_CIT0089","article-title":"Unit Costs of Health and Social Care 2010","author":"Curtis","year":"2010"},{"key":"key\n\t\t\t\t20170520215915_CIT0090","article-title":"NHS 2010\u201311 reference costs publication","author":"Department of Health PbR Team","year":"2011"},{"key":"key\n\t\t\t\t20170520215915_CIT0091","volume-title":"British National Formulary 67","author":"BNF","year":"2014"},{"key":"key\n\t\t\t\t20170520215915_CIT0092","article-title":"Ovarian cancer: the recognition and initial management of ovarian cancer","author":"NICE","year":"2011"},{"key":"key\n\t\t\t\t20170520215915_CIT0093","article-title":"End of life care","author":"NAO","year":"2008"},{"issue":"34","key":"key\n\t\t\t\t20170520215915_CIT0094","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta15340","article-title":"The clinical effectiveness and cost-effectiveness of different surveillance mammography regimens after the treatment for primary breast cancer: systematic reviews registry database analyses and economic evaluation","volume":"15","author":"Robertson","year":"2011","journal-title":"Health Technol Assess"},{"issue":"6","key":"key\n\t\t\t\t20170520215915_CIT0095","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1053\/ejso.2002.1279","article-title":"Clinical experience of prophylactic mastectomy followed by immediate breast reconstruction in women at hereditary risk of breast cancer (HB(O)C) or a proven BRCA1 and BRCA2 germ-line mutation","volume":"28","author":"Contant","year":"2002","journal-title":"Eur J Surg Oncol"},{"key":"key\n\t\t\t\t20170520215915_CIT0096","article-title":"Early and locally advanced breast cancer: diagnosis and treatment","volume-title":"NICE Clinical Guideline, CG80","author":"NICE","year":"2009"},{"issue":"8","key":"key\n\t\t\t\t20170520215915_CIT0097","first-page":"E413","article-title":"Dvd-based genetic counseling is as effective and more cost-efficient than standard-counseling for BRCA testing: results from a randomized trial","volume":"22","author":"Manchanda","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"key\n\t\t\t\t20170520215915_CIT0098","article-title":"Breast Screening Program, England 2008\u201309","author":"Waldron","year":"2010"},{"issue":"3","key":"key\n\t\t\t\t20170520215915_CIT0099","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/sj.bjc.6605155","article-title":"Clinical outcome data for symptomatic breast cancer: the Breast Cancer Clinical Outcome Measures (BCCOM) Project","volume":"101","author":"Bates","year":"2009","journal-title":"Br J Cancer"},{"issue":"9472","key":"key\n\t\t\t\t20170520215915_CIT0100","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials","volume":"365","year":"2005","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170520215915_CIT0101","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/1471-2407-6-210","article-title":"Breast cancer screening in women at increased risk according to different family histories: an update of the Modena Study Group experience","volume":"6","author":"Cortesi","year":"2006","journal-title":"BMC Cancer"},{"issue":"9473","key":"key\n\t\t\t\t20170520215915_CIT0102","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/S0140-6736(05)66481-1","article-title":"Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS)","volume":"365","author":"Leach","year":"2005","journal-title":"Lancet"},{"issue":"1","key":"key\n\t\t\t\t20170520215915_CIT0103","doi-asserted-by":"crossref","first-page":"R8","DOI":"10.1186\/bcr658","article-title":"A combined analysis of outcome following breast cancer: differences in survival based on BRCA1\/BRCA2 mutation status and administration of adjuvant treatment","volume":"6","author":"Robson","year":"2004","journal-title":"Breast Cancer Res"},{"issue":"10","key":"key\n\t\t\t\t20170520215915_CIT0104","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.ejca.2007.01.016","article-title":"Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990\u20131999","volume":"43","author":"Blamey","year":"2007","journal-title":"Eur J Cancer"},{"key":"key\n\t\t\t\t20170520215915_CIT0105","article-title":"Adjuvant! Online: review of evidence concerning its validity, and other considerations relating to its use in the NHS","volume-title":"NICE Clinical Guidelines, No. 80: Early and Locally Advanced Breast Cancer: Diagnosis and Treatment","author":"Gribbin","year":"(2009)"},{"issue":"1","key":"key\n\t\t\t\t20170520215915_CIT0106","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10549-011-1433-2","article-title":"Relative contributions of BRCA1 and BRCA2 mutations to \u201ctriple-negative\u201d breast cancer in Ashkenazi Women","volume":"129","author":"Comen","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"35","key":"key\n\t\t\t\t20170520215915_CIT0107","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1200\/JCO.2012.44.5635","article-title":"Frequency of triple-negative breast cancer in BRCA1 mutation carriers: comparison between common Ashkenazi Jewish and other mutations","volume":"30","author":"Tung","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"key\n\t\t\t\t20170520215915_CIT0108","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/(SICI)1098-2388(200006)18:4<287::AID-SSU3>3.0.CO;2-5","article-title":"Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer","volume":"18","author":"Chappuis","year":"2000","journal-title":"Semin Surg Oncol"},{"issue":"2","key":"key\n\t\t\t\t20170520215915_CIT0109","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10911-005-5399-8","article-title":"Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy","volume":"10","author":"Kozlow","year":"2005","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"key\n\t\t\t\t20170520215915_CIT0110","article-title":"Bone Metastases in Breast Cancer","author":"Lipton","year":"(2006)","journal-title":"Business Briefing: US Oncology Review"},{"issue":"13","key":"key\n\t\t\t\t20170520215915_CIT0111","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.2005.04.3273","article-title":"Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials","volume":"24","author":"Wapnir","year":"2006","journal-title":"J Clin Oncol"},{"issue":"15","key":"key\n\t\t\t\t20170520215915_CIT0112","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1200\/JCO.2008.19.8424","article-title":"Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer","volume":"27","author":"Anderson","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/107\/1\/dju380\/17314137\/dju380.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T12:26:22Z","timestamp":1717590382000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article-lookup\/doi\/10.1093\/jnci\/dju380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,28]]},"references-count":112,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,11,28]]},"published-print":{"date-parts":[[2015,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/dju380","relation":{},"ISSN":["1460-2105","0027-8874"],"issn-type":[{"value":"1460-2105","type":"electronic"},{"value":"0027-8874","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11,28]]}}}